Erenumab
- Generic Name
- Erenumab
- Brand Names
- Aimovig
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1582205-90-0
- Unique Ingredient Identifier
- I5I8VB78VT
- Background
Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specificall...
- Indication
Erenumab is indicated for the preventative treatment of migraine in adults .
- Associated Conditions
- Migraine
- Associated Therapies
- -
Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 112
- Registration Number
- NCT04098250
- Locations
- 🇺🇸
Phoenix VA Health Care System, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 701
- Registration Number
- NCT04084314
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 80
- Registration Number
- NCT04054024
- Locations
- 🇩🇰
Danish Headache Center, Department of Neurology, Rigshospitalet - Glostrup, Glostrup, Denmark
A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT03977649
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 29
- Registration Number
- NCT03912337
- Locations
- 🇺🇸
Research Site, Salt Lake City, Utah, United States
A Controlled Trial of Erenumab in Migraine Prevention
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 261
- Registration Number
- NCT03812224
- Locations
- 🇯🇵
Research Site, Kai-shi, Yamanashi, Japan
Imaging the Migraine Brain Pre- and Post-Erenumab
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 50
- Registration Number
- NCT03773562
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females
- Conditions
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 41
- Registration Number
- NCT02792517
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 34
- Registration Number
- NCT02741310
- Locations
- 🇧🇪
Research Site, Leuven, Belgium
A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 475
- Registration Number
- NCT02630459
- Locations
- 🇯🇵
Research Site, Kai-shi, Yamanashi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.